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ABSTRACT
Non tuberculosis mycobacteria (NTM) could be the causative agents of various clinical infections, especially in
immunocompromised individuals. However, frequency of this bacteria among Mycobacterium isolates is not ye
known. Morover, their pattern of resistance to antituberculosis drugs has not been reported. The aim of the study is
to determine the frequency of NTM among isoniazid resistant Mycobacterium isolates and the pattern of resistance
to antituberculosis drugs. The clinical isolates of isoniazid-resistant mycobacteria collected from several laboratories
in Java were cultured on Lowenstein Jensen (LJ) medium and followed by drug sensitivity testing. Identification of
NTM was based on standard microbiological test: colony morphology, duration of growth, acid fast staining, and
biochemical test (niacin test and nitro benzoic acid medium test). All isolates were resistant to rifampicin, 81.20%
were streptomycin resistant, and half of them were resistant to ethambutol. Pattern of resistance to the second
line antituberculosis drugs (ciprofloxacin, kanamicin, and ofloxacin) was variable with the range of 37,5% to 62,5%.
In conclusion, almost all NTM isolates were resistant to rifampicin and streptomycin, whereas more than half of
isolates were resistant to the second line drugs (ciprofloxacin, kanamicin, and ofloxacin).
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INTRODUCTION
Non tuberculosis mycobacteria (mycobacteria
other than Mycobacterium tuberculosis and M.
leprae) are commonly free-living organisms in the
environment. They live in surface water, tap water,
soil, animals, milk, and food products. The non
tuberculosis mycobacteria can also inhabit skin or
secretions without causing disease. Recently NTM
become important in human infections, since the
number of immunocompromised individuals is
increasing, particularly those with acquired -
immunodeficiency syndrome (AIDS). In broad
terms, NTM is divided into 2 groups i.e.
mycobacteria causing tuberculosis-like disease (M.
kansasii, M. avium-intracellulare complex, M.
scrofulaceum), and those causing soft tissue
infections (M. fortuitum complex, M. marinum, M.
ulcerans).1-5
Several syndromes are caused by NTM. In
children, the most common of these syndromes is
cervical lymphadenitis caused by M. aviumcomplex
(MAC) (including M. aviumis and M. intracellulare),
M. scrofulaceum, M. fortuitum, M. kansasii, and
M. marinum. Less common infections are cutaneous
infection, osteomyelitis, otitis media, and pulmonary
disease. Disseminated infections are almost always
associated with immunodeficiency which is
characterized by impaired cell-mediated immunity,
such as congenital immune defects or human
immunodeficiency virus (HIV) infection. 6
Endogenous infection in HIV patients is usually
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caused by MAC. Mycobacterium fortuitum, M.
chelonae, and M. abscessus that are referred to as
“rapidly growing” mycobacteria can be identified in
the laboratory within 3 to 7 days. Rapidly growing
mycobacteria occasionally have been implicated in
wound, soft tissue, bone, pulmonary, and middle-
ear infections. Manifestations of disseminated NTM
infections depend on the species and route of infect-
ion those include fever, night sweats, weight loss,
abdominal pain, fatigue, diarrhea, and anemia.6,7
Mycobacterium avium complex in the
respiratory or gastrointestinal tract is common in
persons with HIV infection. Non tuberculous
mycobacteria, especially MAC, also can be
recovered from 10% to 20% of adolescents and
young adults with cystic fibrosis. The usual portals
of entry for NTM infection are believed to be
abrasions in the skin (eg., for the cutaneous lesions
causedby M. marinum), the oropharyngeal mucosa
(the presumed portalfor cervical lymphadenitis), the
gastrointestinal or respiratory tract for MAC, and
the respiratory tract (including tympanostomy tubes)
for otitis media and rare cases of mediastinal adenitis
and of endobronchial disease. Most infections
remain localizedat the portal of entry or in regional
lymph nodes. Severe pulmonary disease and
dissemination to distal sites primarily occur in
immunocompromised hosts, especially in persons
with AIDS. No definitive evidence for person-to-
person transmission of NTM. However, cluster of
patients with the same M. avium strain has been
reported and may represent a common
environmental exposure or person-to-personspread.
Cases of otitis media caused by M. abscessus have
been associated with use of contaminated equipment
and water. A waterborne route of transmission has
been suspected for MAC infection in immuno-
deficient hosts.6-9
National wide survey covering 32,000
Mycobacterium isolates in USA from 1979 to 1980
revealed that approximately one-third of
mycobacterial infection were caused by NTM. The
most commonly recognized species were MAC
(61%), M. fortuitum complex (19 %), and M.
kansasii (10 %). 1,7,8,11,12 According to the American
Thoracic Society, recommendation for MAC lung
disease management that the initial therapy for
patients consist of a minimum three-drug regimen
of clarithromycin (or azithromycin), rifampin (or
rifabutin), and ethambutol. In addition, intermittent
streptomycin for the first 2 to 3 months of therapy
is recommended for extensive disease. Recent
randomized trial revealed that a better micro-
biological response is observed in patients treated
with the regimen including streptomycin. For the
treatment of M. abscessus lung disease, combined
intravenous antibiotic therapy including amikacin and
cefoxitin for 2-4 weeks for clinical and microbiologic
improvement was recommended in addition to the
oral antibiotics, including clarithromycin or
azithromycin.13
In Indonesia the frequency of disease due to
NTM has not been reported. The study was
conducted to observe the frequency of NTM among
isoniazid resistant Mycobacterium isolates and to





were collected from several laboratories in Java:
BPLK (Balai Pengembangan Laboratorium
Kesehatan) Surabaya, BKPM (Balai Kesehatan Paru
Masyarakat) Surakarta, BKPM Yogyakarta, RS
Persahabatan Jakarta, BPLK Bandung, and
Microbiology Laboratory Faculty of Medicine,
Gadjah Mada University. The isolates were cultured
on Lowenstein Jensen (LJ) medium for 3-6 weeks.
The study has been approved by the Health
Research Ethics Committee of Faculty of Medicine,
Gadjah Mada University, Yogyakarta.
NTM identification
Non tuberculosis mycobacteria was identified
based on standard microbiological test i.e. colony
morphology, duration of growth on LJ medium, acid
fast staining, and biochemical test (niacin test and
PNB medium test) as described follow :
Niacin test : 3-4 weeks old culture of
mycobacteria on LJ was added with sterile destilled
water scarp off the surface growth. As much as
600 uL of the extract were removed and transfered
to the test tube. One niacin strip was added
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(BBL”Taxo”TB Niacin Test Strip), then the tube
was shook gently. After 12-15 minutes, it was
compare to the negative and positive control extract.
Positive result could be observed by the yellow color
of the liquid, and negative reaction was observed if
no color change of the liquid.
PNB testing: As much as 100 uL of sample
were inoculated on LJ medium which cotains para
nitro benzoic acid (PNB) then incubated for at least
4 week. Only NTM can grow on the medium
whereas M. tuberculosis was inhibited by PNB.
Drugs Sensitivity Testing
Antimycobacterial susceptibility test was
performed by the proportional method as described
elsewhere. In brief, 5 x108 cfu/mL microbial
suspension was prepared according to the Mc
Farland No 1 turbidity standard and diluted 1:10.
As much as 0.2 ml of the diluted microbial
suspension was inoculated to LJ medium with or
without antimycobacterium drugs. The culture tubes
then were incubated at 37oC and growth was
monitored after 3 weeks of incubation. Clinical
isolates were considered resistant to the
antimycobacterium drugs when bacteria growth in
the presence of 1 ìg/mL of isoniazid, 40 ìg/mL of
rifampicin, 2 ìg/mL of streptomycin, or 2 ìg/mL of
ethambutol.
RESULTS
Ninethy-seven samples of isoniazid resistant
mycobacteria were collected during this study.
Differentiation of NTM and their susceptibility test
result are presented on TABLE 1 and 2. TABLE 1
showed that 16.4 % of 97 isolates of mycobacteria
isoniazid resistant were NTM. Most of NTM (40%)
isolates were from Bandung.
TABLE.1 Frequencies of isoniazid-resistant NTM according







Jogjakarta 32 7 21.8
Surakarta 25 2 8.0
Jakarta 10 2 20.0
Surabaya 20 1 5.0
Bandung 10 4 40.0
Total of isolates 97 16 16.4
The susceptibility pattern of NTM isolates to
anti tuberculosis drugs were shown on TABLE 2.
Almost all of the isolates were resistant to rifampicin
and streptomycin and half of them were resistant to
etambuthol. No isolate susceptible to first anti
tuberculosis drugs. Pattern of resistance to the
second line anti tuberculosis drugs was varied, with
the range of 37.5% to 62.5%.
Susceptibility test results showed that most
isolates were resistant to both first and second line
anti tuberculosis drugs. Previous studies reported
that susceptibility of individual NTM to antibiotics
vary considerably. Susceptibility test of NTM should
involve many different antibiotics other than anti
tuberculosis drugs, including that sefalosporine and
macrolide groups.14,15
Among 81.2% isoniazid- resistant isolates in this
study, those were also resistant to rifampicin. In term
of definition of MDR-TB that M.tuberculosis should
be at least resistant to isoniazid and rifampicin, if the
routine culture and drug sensitivity testing of
mycobacteriado not include NTM testing it is possible
that bias interpretation of the result may occur. In other
words, NTM could be misdiagnosed with MDR-TB.
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Notes:
RIF: rifampicin, INH: isoniazid, SM: streptomycin, EMB : ethambutol, CIP: ciprofloxacin,
KM: kanamycin, OFLO: ofloxacin, R: resistance, S: sensitive
TABLE 2. Susceptibility profiles of INH resistant NTM isolates
No
Resistant to first line drug Resistant to second line drug
INH RIF SM EMB CIP KM OFLO
1 R R S S S S R
2 R R R R R R R
3 R S R S R R S
4 R S R S S S S
5 R S R R R R S
6 R R R R R R R
7 R R R R R R S
8 R R R S R S S
9 R R R R S S R
10 R R R R S S R
11 R R R S R S R
12 R R R R S S S
13 R R R S R S R
14 R R S S R S R
15 R R R R S R S










Like in many other countries, the frequency of
NTM in lung infection cases in Indonesia is
unknown. The reasons of this is that the diagnosis
of tuberculosis is mainly based on clinical
presentation and direct microscopic examination of
sputum. Acid fast bacilli staining and conventional
culture can not be used to differentiate NTM from
M. tuberculosis. Unfortunately, identification of
NTM needs several tests (such as niacin, PNB,
and catalase test), however the test unable to
identify the species of mycobacteria. Species
identification of NTM requires complicated
procedures. Nucleic acid detection using specific
probes provide more accurate identification.
Susceptibility testing for NTM should be performed
after recognizing the species of mycobacteria.
However, this method is not recommended for
routine examination, especially in low income
countries. To overcome this problem the
development of simple species identification
technique for NTM is needed.
CONCLUSION
Almost all NTM isolates were resistant to
isoniazid, rifampicin and streptomycin, whereas
more than half of isolates were resistant to the
second line drugs (ciprofloxacin, kanamicin, and
ofloxacin).
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